Gene therapy trials that involve expression of the defective component of the NADPH oxidase complex in hematopoietic stem cells (HSCs) [9–11] and monocyte-derived macrophages [12] obtained from the CGD patients are currently ongoing. Here, FMO5 is linked to chronic granulomatous disease.